Hyperbaric oxygen therapy for late radiation tissue injury (Review)

Bennett MH, Feldmeier J, Hampson N, Smee R, Milross C

THE COCHRANE COLLABORATION®

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2009, Issue 3

http://www.thecochranelibrary.com

TABLE OF CONTENTS

[Intervention Review]

Hyperbaric oxygen therapy for late radiation tissue injury

Michael H Bennett[1], John Feldmeier[2], Neil Hampson[3], Robert Smee[4], Christopher Milross[5]

[1]Anaesthesia Department, Prince of Wales Hospital, Randwick, Australia. [2]Dept of Radiation Oncology, Medical College of Ohio, Toledo, Ohio, USA. [3]Centre for Hyperbaric Medicine, Virginia Mason Medical Centre, Seattle, Washington State, USA. [4]Department of Radiation Oncology, Prince of Wales Hospital, Randwick, Australia. [5]Department of Radiation Oncology, Sydney Cancer Centre, Camperdown , Australia

Contact address: Michael H Bennett, Anaesthesia Department, Prince of Wales Hospital, Barker Street, Randwick, NSW, 2031, Australia. m.bennett@unsw.edu.au. (Editorial group: Cochrane Gynaecological Cancer Group.)

Cochrane Database of Systematic Reviews, Issue 3, 2009 (Status in this issue: *Unchanged*)

DOI: 10.1002/14651858.CD005005.pub2
This version first published online: 20 July 2005 in Issue 3, 2005.
Last assessed as up-to-date: 22 August 2008. (Help document - Dates and Statuses explained)

This record should be cited as: Bennett MH, Feldmeier J, Hampson N, Smee R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. *Cochrane Database of Systematic Reviews* 2005, Issue 3. Art. No.: CD005005. DOI: 10.1002/14651858.CD005005.pub2.

ABSTRACT

Background

Cancer is a significant global health problem. Radiotherapy is a treatment for many cancers and about 50% of patients having radiotherapy with be long-term survivors. Some will experience late radiation tissue injury (LRTI) developing months or years later. Hyperbaric oxygen therapy (HBOT) has been suggested as a treatment for LRTI based upon the ability to improve the blood supply to these tissues. It is postulated that HBOT may result in both healing of tissues and the prevention of problems following surgery.

Objectives

To assess the benefits and harms of hyperbaric oxygen therapy for treating or preventing late radiation tissue injury.

Search strategy

We searched The Cochrane Central Register of Controlled Trials (CENTRAL Issue 3, 2008), MEDLINE, EMBASE, CINAHL and DORCTHIM (hyperbaric RCT register) from inception to August 2008.

Selection criteria

Randomised controlled trials (RCTs) comparing the effect of HBOT versus no HBOT on LRTI prevention or healing.

Data collection and analysis

Three review authors independently evaluated the quality of the relevant trials using the guidelines of the Cochrane Handbook and extracted the data from the included trials.

Main results

Eight trials contributed to this review (566 participants). For pooled analyses, investigation of heterogeneity suggested important variability between trials. From single studies there was a significantly increased chance of improvement or cure following HBOT for radiation proctitis (relative risk (RR) 1.72, 95% confidence interval (CI) 1.0 to 2.9, P = 0.04, numbers needed to treat (NNT) = 5), and following both surgical flaps (RR 8.7, 95% CI 2.7 to 27.5, P = 0.0002, NNT = 4) and hemimandibulectomy (RR 1.4, 95% CI 1.1 to 1.8, P = 0.001, NNT = 5). There was also a significantly improved probability of healing irradiated tooth sockets following dental extraction (RR 1.4, 95% CI 1.1 to 1.7, P = 0.009, NNT = 4).

There was no evidence of benefit in clinical outcomes with established radiation injury to neural tissue, and no data reported on the use of HBOT to treat other manifestations of LRTI. These trials did not report adverse effects.

Authors' conclusions

These small trials suggest that for people with LRTI affecting tissues of the head, neck, anus and rectum, HBOT is associated with improved outcome. HBOT also appears to reduce the chance of osteoradionecrosis following tooth extraction in an irradiated field. There was no such evidence of any important clinical effect on neurological tissues. The application of HBOT to selected patients and tissues may be justified. Further research is required to establish the optimum patient selection and timing of any therapy. An economic evaluation should be also be undertaken. There is no useful information from this review regarding the efficacy or effectiveness of HBOT for other tissues.

PLAIN LANGUAGE SUMMARY

Hyperbaric oxygen (HBO) for the treatment of the late effects of radiation therapy

There is a risk of serious complications developing after radiation treatment for cancer (late radiation tissue injury (LRTI). Hyperbaric oxygen therapy (HBOT) involves breathing oxygen in a specially designed chamber. It is used as a treatment to improve oxygen supply to damaged tissue and stimulate healing.

We found some evidence that LRTI affecting the head, neck and lower end of the bowel can be improved with HBOT. There is little evidence for or against benefit in other tissues affected by LRTI. Our conclusions are based on eight randomised trials with a limited number of patients. Further research is needed.

BACKGROUND

Cancer is a significant global health problem. According to World Health Organization statistics, more than 10 million people are diagnosed with cancer every year, and it is estimated there will be 15 million new cases every year by 2020. Cancer causes 6 million deaths every year or 12% of deaths worldwide (WHO 2004). Radiotherapy is a well-established treatment of suitable malignancies in a wide variety of anatomical areas. Of the approximately 1.2 million new cases of invasive cancer diagnosed annually in the USA, for example, about 50% will receive radiation therapy (Jemal 2002), and of these, about 50% will be long-term survivors. While radiation therapy may acutely injure any normal tissue in the path of the radiation, this acute injury generally resolves following completion of the treatment course. Serious, radiation-related complications developing months or years after radiation treatment, collectively known as late radiation tissue injury (LRTI), are relatively rare and will significantly affect between 5% and 15% of those long-term survivors who received radiation therapy, although the incidence varies widely with dose, age and site (Rubin 1968; Stone 2003; Thompson 1999; Waddell 1999). Although any tissue may be affected, LRTI is in practice most common in the head and neck, chest wall, breast and pelvis - reflecting the anatomical areas most commonly irradiated and the likelihood of survival for patients treated for cancer at these anatomical sites.

When late radiation injuries occur, tissues undergo a progressive deterioration characterised by a reduction in the density of small blood vessels (reduced vascularity) and the replacement of normal tissue cells with dense fibrous tissue (fibrosis), until there is insufficient oxygen supplied to sustain normal function. This situation is frequently exacerbated by secondary damage due to infection or surgery in the affected area (Rubin 1984). This progressive and delayed radiation damage may reach a critical point where the tissue breaks down to form an ulcer or area of cell death (radiation necrosis, or radionecrosis). LRTI can affect any organ system, although some tissues are more sensitive to radiation effects than others (Thompson 1999; Trott 1984; Waddell 1999).

Historically, the management of these injuries has been unsatisfactory. LRTI may be life threatening and may significantly reduce quality of life. Conservative treatment is usually restricted to symptom management, while definitive treatment traditionally entails surgery to remove the affected part and extensive repair (Stone 2003). Surgical intervention in an irradiated field is often disfiguring and associated with an increased incidence of delayed healing, breakdown of a surgical wound or infection.

HBOT has been proposed to improve tissue quality, promote healing and prevent breakdown of irradiated tissue fields. It may be defined as the therapeutic administration of 100% oxygen at environmental pressures greater than one atmosphere absolute (ATA). Administration involves placing the patient in an airtight vessel,

increasing the pressure within that vessel, and giving 100% oxygen for respiration. In this way, it is possible to deliver a greatly increased pressure of oxygen to the lungs, blood and tissues. Typically, treatments involve pressurisation to between 2.0 and 2.5 ATA for periods between 60 and 120 minutes once or twice daily to a total of 30 to 60 sessions of treatment.

The intermittent application of HBO is the only intervention that has been shown to increase the number of blood vessels in irradiated tissue. This has been demonstrated by Marx in a rabbit mandibular (jaw bone) model and further confirmed by serial tissue oxygen level measurements using electrodes placed on the overlying skin (transcutaneous oximetry) in humans undergoing a course of therapy for radiation necrosis of the mandible (Marx 1988; Marx 1990). In the rabbit study, the jaw and surrounding soft tissues were heavily irradiated and one group 'rescued' with HBO six months later. The 2 control groups showed no improvement while a series of 20 sessions at 2.4 atmospheres absolute (ATA) on 100% oxygen returned the density of blood vessels to 80% of normal. In the human study, a progressive recovery of low transcutaneous oximetry readings into the normal range was achieved in a group of patients receiving therapy for underlying osteoradionecrosis (radiation necrosis of bone).

HBOT seems most likely to achieve such improvements through a complex series of changes in affected tissues. Tissue swelling is probably improved through an osmotic effect of oxygen, while the establishment of a steep oxygen gradient across an irradiated tissue margin is a powerful stimulus to the growth of new blood vessels(Davis 1988; Hills 1999). In addition, improving oxygen levels will improve white cell and fibroblast function, further enhancing wound healing (Mandell 1974). Improved tissue quality has been demonstrated in a model of radiation small bowel injury (Feldmeier 1995; Feldmeier 1998).

While HBOT has been used for LRTI since at least 1975 (Mainous 1975), most clinical studies have been limited to relatively small case series or individual case reports. There have been relatively few comparative studies published, and no previous quantitative systematic reviews of which we are aware. In a recent semi-quantitative review, Feldmeier and Hampson located 71 such reports involving a total of 1193 patients across 8 different tissues (Feldmeier 2002). In these patients, for whom conservative treatment had failed to improve symptoms, there were clinically significant improvements in the majority of patients. Results varied between tissue types, with neurological tissue appearing the most resistant to improvement. Only 7 of 71 reports indicated a generally poor response to HBOT. The present review will complement Feldmeier 2002 by using explicit Cochrane methodology to locate, quantitatively appraise and summarise the comparative data, while not discussing in any detail the non-comparative series summarised in that review.

HBOT is associated with some risk of adverse effects including damage to the ears, sinuses and lungs from the effects of pressure, temporary worsening of short sightedness (myopia), claustrophobia and oxygen poisoning. Although serious adverse events are rare, HBOT cannot be regarded as an entirely benign intervention. It has further been suggested that HBOT may increase the incidence and rate, or both of growth of tumours in patients with a history of malignancy. A recent comprehensive review fails to support these concerns (Feldmeier 2003).

OBJECTIVES

The objectives of this review were to determine the efficacy and safety of HBOT in the treatment of patients with late radiation tissue injury.

Specifically we addressed the following questions:

- Is a course of HBOT more efficacious than placebo or no treatment in improving symptoms, signs and disability for patients with LRTI?
- Is a course of HBOT more efficacious than placebo or no treatment in preventing further deterioration for patients with LRTI?
- Is HBOT administration safe?

METHODS

Criteria for considering studies for this review

Types of studies

Randomised and pseudo-RCTs that compared the effect of a regimen including HBOT on any form of late radiation tissue injury, with any treatment regimen not including HBOT.

Types of participants

Any person with late radiation tissue injury (including necrosis) of whatever tissue. We also accepted patients treated with large dose radiation therapy likely to induce relatively early necrosis (e.g. radiosurgery to a brain lesion).

Types of interventions

We accepted trials comparing regimens which included HBOT with similar regimens that excluded HBOT. Where co-interventions differed significantly between studies this was clearly stated and the implications discussed.

The intervention under examination was HBOT administered in a compression chamber between pressures of 1.5 ATA and 4.0 ATA

and treatment times between 30 mins and 120 mins daily or twice daily. These parameters exclude trivial treatments on the one hand, and highly toxic exposures on the other. The comparator group was diverse, and we accepted any standard treatment regimen designed to promote tissue healing or prevent further deterioration.

Types of outcome measures

Appropriate outcome measure depended on the nature of the LRTI and the anatomical location. Studies were eligible for inclusion if they reported any of the following outcome measures:

All anatomical areas

Primary outcome measures:

(1) Survival
(2) Complete resolution of necrosis or tissue damage
(3) Complete resolution or substantial improvement of necrosis or tissue damage
(4) Improvement in LENT-SOMA scale
[The LENT-SOMA scales (Late Effects Normal Tissues - Subjective, Objective, Management, Analytic) were developed jointly by the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) in 1995 in order to standardise assessment of LRTI (Pavy 1995). Scales are location specific and have been summarised in a number of forms for each location. The implications for pooling are discussed as required. The scale dimensions are summarised in Table 1.]

Table 1. The LENT-SOMA Scales - Conceptual summary

(S)ubjective	(O)bjective	(M)edical management	(A)nalytic
The injury from the patient point of view. May involve interview, diary or questionnaire depending on the system to be used.	Morbidity assessed objectively by clinician during physical examination.	The active steps that have been taken in order to ameliorate the symptoms.	Diagnostic and imaging tools used to further objectively define the level of injury.

Secondary outcome measures:

(5) Resolution of pain
(6) Resolution of swelling
(7) Improvement in quality of life (QOL) and/or function

(8) Osteoradionecrosis (ORN)

Primary outcome measures:

(a) Healing with complete soft tissue coverage over bone
(b) Resolution of sinus tract between bone and skin or mucosa
(c) Resolution of fracture or re-establishment of bony continuity
(d) Development of ORN in tooth socket following extraction

Secondary outcome measures:

(e) Improvement in X-Ray appearance

(9) Head and neck soft tissues

Primary outcome measures:

(a) Wound dehiscence (breakdown of a surgical wound)
(b) Surgical removal of larynx
(c) Major vessel bleeding

Secondary outcome measures:

(d) Speed of wound healing
(e) Improvement in swelling or 'woodiness' of tissue
(f) Reversal of tracheostomy (surgical breathing hole in the trachea)

(10) Urinary bladder

Primary outcome measures:

(a) Resolution of bleeding
(b) Removal of bladder and urine diversion procedures

Secondary outcome measures:

(c) Improved cystoscopic appearance
(d) Frequency
(e) Dysuria (pain on passage of urine)

(11) Chest wall

Nil additional to those listed under 'All anatomical areas'.

(12) Bowel

Primary outcome measures:

(a) Resolution of bleeding
(b) Operations on the bowel such as colostomy, ileostomy or bowel resection

Secondary outcome measures:

(c) Improvement in pain score

(13) Neurological tissue

Primary outcome measures:

(a) Improvement in objective motor function
(b) Improvement in visual acuity

Secondary outcome measures:

(c) Improvement in sensory function
(d) Improvement in functional ability or activities of daily living
(e) Improvement in neuropsychiatric testing
(f) Improvement in X-ray or scan appearance
(g) Reduction in steroid dose

Extremities

Nil additional to those listed under 'All anatomical areas'.

Adverse events of HBOT

(a) Recurrence of tumour (locally or remote)
(b) Visual disturbance (short and long term)
(c) damage from pressure (aural, sinus or pulmonary barotrauma, in the short and long-term)
(d) Oxygen toxicity (short-term)
(e) Withdrawal from treatment for any reason
(f) Any other recorded adverse effect

Search methods for identification of studies

Electronic searches

It was our intention to capture both published and unpublished studies.
We searched: Cochrane Register of Controlled Trials (CENTRAL), Issue 3, 2008 (The Cochrane Library; inception to August 2008), MEDLINE (1950 to August 2008), EMBASE (inception to August 2008), CINAHL (inception to August 2008) and an additional database developed in our hyperbaric facility, The Database of Randomised Trials in Hyperbaric Medicine (1998 to August 2008, Bennett 2004). The search strategies are given in Appendix 1, Appendix 2,Appendix 3, Appendix 4 and Appendix 5.

Searching other resources

- Experts in the field and leading hyperbaric therapy centres (as identified by personal communication and searching the Internet) were contacted and asked for additional relevant data in terms of published or unpublished randomized trials.
- Handsearch of relevant hyperbaric textbooks (Kindwall, Jain, Marroni, Bakker, Bennett and Elliot), journals (Undersea and Hyperbaric Medicine, Hyperbaric Medicine Review, South Pacific Underwater Medicine Society (SPUMS) Journal, European Journal of Hyperbaric Medicine and Aviation, Space and Environmental Medicine Journal) and conference proceedings (Undersea and Hyperbaric Medical Society, SPUMS, European Undersea and Baromedical Society, International Congress of Hyperbaric Medicine) published since 1980.
- Contacted of authors of relevant studies to request details of unpublished or ongoing investigations.
- Examination of the reference list of all trials for inclusion in this review.

All languages were considered. Authors were contacted if there was any ambiguity about the published data.

Data collection and analysis

Data retrieval and management

One review author (MB) was responsible for handsearching and identification of appropriate studies for consideration and all possibly relevant studies were entered into a bibliographic software package (Review Manager). Three review authors (MB, JF and NH) then examined the electronic search results and identified comparative studies that may have been relevant. Studies were retained when one or more review authors identified them as appropriate. Retained studies were retrieved in full and reviewed independently by three review authors, all with content expertise in HBOT, one with content expertise in radiation oncology (JF). In addition one of the review authors (MB) has expertise in clinical epidemiology. Review authors recorded data using the data extraction form developed for this review.

Data extraction

Each review author independently extracted the relevant data. Primary authors were contacted to provide information when missing data was encountered or if necessary data such as adverse events were not clearly stated. All differences were resolved by discussion among the review authors and no disputed trials required referral to the Review Group contact editor for appraisal.

Quality assessment

Study quality was assessed using an adaptation of the method outlined in Schulz (Schulz 1995), and recommendations made for inclusion or exclusion from the review. Results from the study quality assessment are presented in a descriptive manner. The following characteristics were assessed:

Adequacy of the randomization process

A - Adequate sequence generation is reported using random number tables, computer random number generator, coin tossing, or shuffling;
B - Did not specify one of the adequate reported methods in (A) but mentioned randomization method;
C - Other methods of allocation that appear to be unbiased.

Adequacy of the allocation concealment process

A - Adequate measures to conceal allocations such as central randomization; serially numbered, opaque, sealed envelopes; or other description that contained convincing elements of concealment;
B- Unclearly concealed trials in which the author either did not report an allocation concealment approach at all, or reported an approach that did not fall into one of the categories in (A);
C- Inadequately concealed trials in which method of allocation is not concealed such as alternation methods or use of case record numbers.

Potential for selection bias after allocation

A- Trials where an intention-to-treat analysis is possible and few losses to follow-up are noted;
B- Trials which reported exclusions (as listed in A but exclusions were less than 10%);
C- No reporting on exclusions or exclusions greater than 10% or wide differences in exclusions between groups.

Level of masking (treatment provider, patient, outcome assessor)

A- Double or triple-blind;
B- Single-blind;
C- Non-blind.
These four factors were considered for possible sensitivity analysis.

Analyses

It was our intention where possible to analyse the data from different anatomical sites together (see outcomes listed under 'all anatomical areas'). However, many outcomes are specific to a particular anatomical site, and these outcomes were analysed separately. All comparisons were made using an intention-to-treat analysis where possible and reflect efficacy in the context of randomized trial
ing, rather than true effectiveness in any particular clinical context. While we planned to compare survival over time using the log Hazard Ratio and variance (Parmar 1998), no suitable data was available. For dichotomous outcomes RR was used. For continuous data, the mean difference (MD) between treatment and control arms in each trial was calculated and aggregated using inverse variance weights to estimate an overall MD and its 95% CI. We used a fixed-effect model where there was no evidence of significant clinical heterogeneity between studies (see below), and employed a random effects model when such heterogeneity was likely. All statistical analysis was performed using RevMan software.
Where co-interventions differed significantly between studies this was clearly stated and the implications discussed.

Overall primary outcomes (All anatomic areas)

(1) Survival. For each trial, we calculated the RR for survival in the HBOT group compared to the control group. These RRs were pooled in a meta-analysis to estimate an overall RR and its 95% CI. A statistically significant difference between experimental intervention and control intervention was assumed if the 95% CI of the RR did not include the value 1.0. As an estimate of the clinical relevance of any difference between experimental intervention and control intervention, we calculated the number needed to treat (NNT) and number needed to harm (NNH) with 95% CI as appropriate, using the formula NNT = 1/RD with 95% CI calculated from the 95% CI of the RR, following the method recommended in Altman 2001.

(2) Complete resolution of necrosis or tissue damage. The RR for complete resolution of necrosis or tissue damage with and without HBOT was calculated using the methods described in (1) above.
(3) Improvement in LENT-SOMA scales. For each trial, the mean difference (MD) in this score between HBOT and control groups was to be calculated and combined in a meta-analysis to estimate an overall MD and its 95% CI. No trials reported this outcome.

Overall secondary outcomes

(4) Radiological improvement. Statistical analysis would depend on the nature of the data, but would have followed the methods outlined above. No trials reported this outcome.
The outcomes for each anatomical site will be approached in an analogous manner to that outlined above.
(5) Adverse events . For each trial, we planned to calculate the RR for each adverse event in the HBOT compared to the control group. These RRs were to be pooled in a meta-analysis to estimate an overall RR and its 95% CI. No trials reported this outcome.

Sensitivity analyses

We intended to perform sensitivity analyses for missing data and study quality where appropriate.

Missing data

We employed sensitivity analyses using different approaches to imputing missing data. The best-case scenario assumed that none of the originally enrolled patients missing from the primary analysis in the treatment group had the negative outcome of interest whilst all those missing from the control group did. The worst case scenario was the reverse.

Study quality

If appropriate, we had planned to conduct a sensitivity analysis by study quality based on the presence or absence of a reliable random allocation method, concealment of allocation and blinding of participants or outcome assessors.

Heterogeneity

Heterogeneity was assessed using the I^2 statistic and consideration given to the appropriateness of pooling and meta-analysis.

Subgroups

We considered subgroup analysis based on:

- Anatomical location
- Dose of oxygen received (pressure, time and length of treatment course)
- Nature of the comparative treatment modalities
- Severity of injury

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies.
Following our updated search in August 2008, we have identified a total of 116 publications apparently dealing with the use of HBOT for the treatment of LRTI. Initial examination confirmed 66 were case reports or case series, 25 were reviews or letters without new data, four were comparative trials in radiation enhancement or dental implant survival, one was a retrospective cohort study, one was a report of a planning workshop and one was a report of animal work. These reports were excluded, leaving 18 possible randomised comparative trials. After appraisal of the full reports we further excluded five reports with non-random controls (Carl 2001; Gal 2003; Granstrom 1999; Maier 2000; Niimi 1997), two systematic reviews (Coulthard 2002; Denton 2002) with no further randomised data and one randomised trial with no quantitative data (Tobey 1979). See table 'Characteristics of excluded studies'. The other ten reports were accepted into the review (Annane 2004; Clarke 2004; Clarke 2008; Hulshof 2002; Marx 1985; Marx 1999a; Marx 1999b; Pritchard 2001; Sidik 2007). The tenth report is a letter (Yarnold 2005) outlining long-term follow-up in the study originally published by Pritchard (Pritchard 2001). Marx 1999a and Marx 1999b are trials reported for the first time in a textbook. The recruitment period for these studies is not known. Clarke 2008 is the full report of results previously reported only in abstract in Clarke 2004, and the later report is now the primary reference for this trial. We have not yet been able to obtain a copy of Sidik 2007 (see table 'Characterisitics of studies awaiting classification').
The included trials were published between 1985 and 2008, and the reviewers are aware there is a large, multicentre trial underway into the effect of HBOT on seven further different manifestations of LRTI. Clarke 2008 is the report of one arm of that trial (radiation proctitis). In total, these trials include data on 566 participants, 284 receiving HBOT and 282 control. The largest (Marx 1999b) accounts for 28% of cases. (See Table: 'Characteristics of included studies').
Where sex was specified, most trials enrolled more females than males (Pritchard 2001 enrolled 34 participants, all female; Hulshof 2002 six females and one male; Clarke 2008 106 females and 13 males). Only Annane 2004 enrolled more males (59 males, nine females). With regard to age, Pritchard 2001 enrolled participants from 40 to 79 years, in Hulshof 2002 the average age was 46 years and in Annane 2004 the median age was 53 in the HBOT group and 55 in the controls. Two studies did not specify any such characteristics except prior exposure to 6400 cGy in the area under investigation (Marx 1999a; Marx 1999b). The other five studies specified exclusion of those unfit for compression or the presence of residual tumour, while Marx 1985 also excluded those

with penicillin sensitivity, recent chemotherapy or concurrent disease known to effect wound healing and Annane 2004 excluded those with more advanced disease . No details of prior therapy for the pathology under study were given, while Marx 1985 specified a minimum prior radiation dose of 6000 cGy at least six months prior to enrolment. Clarke 2008 entered participants with radiation proctitis, Annane 2004 those with established osteoradionecrosis of the mandible, Hulshof 2002 those with cognitive deficits following brain irradiation with at least 30 Gy, Pritchard 2001 radiation-induced brachial plexus lesions, Marx 1999a candidates for hemimandibular jaw reconstruction, Marx 1999b candidates requiring major soft tissue surgery or flaps, and Marx 1985 participants requiring tooth extraction.

Both the dose of oxygen per treatment session and for the total course of treatment varied between studies. The lowest pressure administered was 2.0 ATA (Clarke 2008) and the highest 3.0 ATA (Hulshof 2002), while all other trials utilised 2.4 ATA. The duration of all treatments was 90 minutes. All trials administered a total of 30 treatments except Annane 2004 and Clarke 2008, where some individuals received 40 treatments.Annane 2004 used a twice daily treatment schedule.

There were no active comparator regimens administered to the control arms but withheld from the HBOT arm of these trials. Three trials administered a blinded sham therapy (Annane 2004; Clarke 2008; Pritchard 2001) Details are given in the table 'Characteristics of included studies'.

The follow-up periods varied from immediately after therapy (Clarke 2008), to three weeks following the treatment course (Marx 1999b), six months (Hulshof 2002; Marx 1985) and one year (Annane 2004; Pritchard 2001). Marx 1999a did not specify the time at which outcome was measured. All included studies reported at least one clinical outcome of interest. Of the outcomes identified above, these trials reported data on primary outcomes (resolution of problem, bony continuity established, mucosal cover, wound dehiscence and LENT-SOMA scale) and secondary outcomes (oedema resolution, pain scores, QOL, physical functioning, sensory function and neuropsychiatric testing).

Other outcomes (including non-clinical) reported included: radiological changes (Annane 2004), self-rated memory and dexterity (Hulshof 2002), sensory action potentials (Pritchard 2001), post-surgical complication rate (Marx 1999a) and wound infection rate (Marx 1999b).

Risk of bias in included studies

Details of the quality assessment are given in the table 'Characteristics of included studies'. Study quality varied widely, however, because very few analyses could be pooled, study quality was not used as a basis for sensitivity analysis.

Allocation concealment

Allocation concealment was adequately described in four studies (Annane 2004; Clarke 2008; Hulshof 2002; Pritchard 2001), all used a remotely located randomisation officer. For none of the remaining studies is there a clear indication that the investigators were unable to predict the prospective group to which a participant would be allocated.

Randomisation

Randomisation procedures were described in three studies (Annane 2004; Clarke 2008; Pritchard 2001), all employing a computer generated random number table, but not in the other four.

Subject baseline characteristics

Given the variation in pathology outlined in 'Description of Studies' above, it is not surprising that there is considerable variation in patient baseline characteristics. Two studies did not specify any baseline characteristics except prior exposure to 6400 cGy in the area under investigation (Marx 1999a; Marx 1999b). The other five studies specified exclusion of those unfit for compression. The subjects in Annane 2004 had two months of prior therapy with antibiotics, wound irrigation and surgery, but no details were given in the other studies. Marx 1985 specified a minimum prior radiation dose of 6000 cGy at least six months prior to enrolment.

Blinding

Three studies utilised a sham therapy in order to mask subjects and outcome assessors to HBOT (Annane 2004; Clarke 2008; Pritchard 2001), while no sham was employed in the remaining four studies (Hulshof 2002; Marx 1985; Marx 1999a; Marx 1999b). Only Clarke 2008 formally tested the success of the blinding strategy.

Patients lost to follow-up

Six studies did not report any losses to follow-up or violation of the study protocol (Annane 2004; Hulshof 2002; Marx 1985; Marx 1999a; Marx 1999b; Pritchard 2001). Clarke 2008 did not include 19 control subjects and 11 HBOT group subjects in the analysis because they did not complete the therapy protocol, and there was one further subject lost to follow-up at the end of treatment. Sensitivity analysis using best and worse case scenarios were performed where this study contributed data to the analysis.

Intention-to-treat analysis

Only Pritchard 2001 specifically detailed an intention to treat analysis (two subjects in the HBOT group did not complete therapy, but were included in analysis). Five of the remaining six studies reported full follow-up and did not report any protocol violation (see above).

Effects of interventions

Combined anatomical areas

Primary outcomes

(1) Death (comparison 01)

Annane 2004 reported two deaths in each group at one year, two from cancer regrowth and two from other causes not related to their ORN (the RR of dying following HBOT is estimated at 1.2, 95% CI 0.18 to 7.99). Clarke 2008 reported five deaths at one year, but this crossover study did not identify the original treatment allocation.

(2) Complete resolution of tissue damage or necrosis (comparison 02)

(a) Complete resolution of clinical problem at or before three months (comparison 02, outcomes 01, 02, 03)

Four trials reported this outcome (Annane 2004; Clarke 2008; Marx 1999a; Pritchard 2001), involving 325 participants (57% of the total participants in this review), with 163 randomised to HBOT and 162 to control. Overall, 59 (36%) of participants in the HBOT arm achieved resolution, versus 46 (28%) in the control arm. Analysis for heterogeneity suggested the high proportion of variability between trials was not due to sampling variability (I^2 = 82%), and we have not quantified an overall estimate of effect. Pritchard 2001 did not report any participants with resolution in either arm, so could not contribute to the analysis.

There was a significantly improved probability of resolution with the administration of HBOT for patients requiring hemimandibulectomy (RR 1.4, 95% CI 1.1 to 1.8, P = 0.001, Marx 1999a) and a non-significant improvement for radiation proctitis (RR 9.80, 95%CI 0.6, 173.3, P = 0.12, Clarke 2008). The result for proctitis was however, highly sensitive to the allocation of dropouts (best case: RR 35, 95%CI 2.14 to 571.6, P = 0.01; worst case: RR 0.26, 95% CI 0.1 to 0.67, P = 0.005). For participants requiring hemimandibulectomy, 48 (92%) achieved resolution following HBOT versus 34 (65%) in the control group, and the number needed to treat (NNT) to achieve one extra case of resolution is 4, (95% CI 2 to 8). On the other hand, there was no improvement in the chance of resolution for patients with osteoradionecrosis of the mandible in the Annane 2004 study (RR 0.6, 95% CI 0.25 to 1.4, P = 0.24). See Figure 1

Figure 1. Forest plot of comparison: 2 Complete resolution of problem, outcome: 2.1 Complete resolution of clinical problem at end of therapy to three months.



(3) Complete resolution or significant improvement of tissue damage or necrosis (comparison 03, outcomes 01, 02, 03)

Clarke 2008 reported this combined outcome immediately after completion of therapy. This trial reported on 119 participants (21% of the total in this review), with 63 randomised to HBOT and 56 to control. 29 (46%) of participants in the HBOT arm achieved this outcome versus 15 (27%) in the control arm. This difference was statistically significant (RR for improvement in HBOT 1.72, 95% CI 1.0 to 2.9, P = 0.04), but is sensitive to the allocation of dropouts and those missing (best case: RR 2.73, 95% CI 1.66 to 4.49, P < 0.0001; worst case: RR 0.66, 95% CI 0.47 to 0.93, P = 0.04). This analysis suggests we would have to treat five patients with HBOT in order to achieve one extra favourable outcome (NNT 5, 95% CI 3 to 23).

(4) LENT-SOMA scores (comparison 04)

(a) Improvement in LENT-SOMA score at completion of therapy
Only one trial reported this outcome (Clarke 2008) involving 150 subjects (27% of the total), with 75 randomised to both HBOT and control. The mean improvement in LENT-SOMA score was greater in the HBOT group (5.0 versus 2.6), and this difference was statistically significant (MD 2.4, 95% CI 0.88 to 3.9, P = 0.002).

Secondary outcomes

(5) Pain scores (comparison 04)

(a) Change in pain score (0 to 100 scale) from baseline to six months after treatment (comparison 05, outcome 01)
Only one trial reported this outcome (Pritchard 2001) involving 34 patients (6% of the total) with 17 randomised to both HBOT and control. Pain scores increased over this time period in both groups, but more so with HBOT (5.3 points versus 1.2). Standard deviations were not reported around these means, precluding further analysis.
(b) Change in pain score (0 to 100 scale) from baseline to 12 months after treatment (comparison 05, outcome 02)
Only one trial reported this outcome (Pritchard 2001) involving 34 patients (6% of the total) with 17 randomised to both HBOT and control. Pain scores were reduced in both groups, but more so in the controls (-5.0 points versus -0.7). Standard deviations were not reported around these means, precluding further analysis.

(6). Swelling (comparison 06)

(a) Resolution of lymphoedema in arm at six months (comparison 06, outcome 01)
Only one trial reported this outcome (Pritchard 2001) involving 34 patients (6% of the total) with 17 randomised to both HBOT and control. Two subjects (12%) in the HBOT arm achieved resolution, while none in the control group did so. This difference in favour of HBOT was not statistically significant (RR of resolution with HBOT 5.0, 95% CI 0.3 to 97.0, P = 0.29).

(7) Quality of life or functional scores (comparison 07)

(a) SF-36 score for general health at 12 months (comparison 07, outcome 01)
Only one trial reported this outcome (Pritchard 2001) involving 34 patients (6% of the total) with 17 randomised to both HBOT and control. The mean score for general health self-rating was lower in the HBOT group (58.8 versus 61.1), but not significantly so (WMD -2.3, 95% CI -19.0 to 14.4, P = 0.79).
(b) SF-36 score for physical functioning at 12 months (comparison 07, outcome 02)
Only one trial reported this outcome (Pritchard 2001) involving 34 patients (6% of the total) with 17 randomised to both HBOT and control. The mean score for self-rating of physical functioning was lower in the HBOT group (53.5 versus 57.5), but not significantly so (WMD -4.0, 95% CI -19.4 to 11.4, P = 0.61). (c) Bowel bother subscale at completion of therapy (comparison 07, outcome 03) Only one trial reported this outcome (Clarke 2008) involving 150 patients (27% of the total) with 75 randomised to each of HBOT and sham therapy. This trial reported a statistically significant mean improvement of 14.1% (P = 0.0007) in this subscale following HBOT compared to a non-significant mean improvement of 5.8%(P = 0.15) in the sham group.

(8) Osteoradionecrosis

Primary outcomes

(a) Achievement of complete mucosal cover (comparison 08, outcome 01)
Three trials reported this outcome (Annane 2004; Marx 1985; Marx 1999a), involving 246 subjects (43% of the total), with 120 randomised to HBOT and 126 to control. 101 (84%) of subjects in the HBOT arm achieved mucosal cover, versus 82 (65%) in the control group. Heterogeneity was moderate (I^2 = 27%), and explained by the addition of data from Annane 2004 (I^2 = 0% without Annane). Overall, there was a significantly improved probability of attaining mucosal cover with the administration of HBOT (RR 1.3, 95% CI 1.1 to 1.6, P = 0.003). The NNT to achieve one further case with mucosal cover with the application of HBOT is 5, (95% CI 3 to 12). See Figure 2.

Figure 2. Forest plot of comparison: 8 Osteoradionecrosis, outcome: 8.1 Complete mucosal cover.



(b) Resolution of sinus tract (comparison 08, outcome 03)
No study reported data on this outcome

(c) Establishment of bony continuity (comparison 08, outcome 02)
Only one trial contributed results to this outcome (Marx 1999a) involving 104 subjects (18% of the total), 52 randomised to both HBOT and control. Forty eight (92%) of subjects in the HBOT arm achieved continuity, versus 60 (65%) in the control group. There was a significantly improved probability of attaining bony continuity with the administration of HBOT (RR 1.4, 95% CI 1.1 to 1.8, P = 0.001). The NNT to achieve one further case with bony continuity with the application of HBOT is 4, (95% CI 2 to 8).
(d) Healing of tooth sockets following extraction in irradiated field at six months (comparison 08, outcome 03)
Only one trial contributed results to this outcome (Marx 1985) involving 74 subjects (13% of the total), 37 randomised to both HBOT and control. 35 (95%) of subjects in the HBOT arm achieved healing of all sockets, versus 26 (70%) in the control group. There was a significantly improved probability of healing with the administration of HBOT (RR 1.4, 95% CI 1.1 to 1.7, P = 0.009). The NNT with HBOT to achieve one further case with all tooth sockets healed is 4, (95% CI 2 to 13).
Secondary outcomes

(e) Improvement in X-Ray appearance (comparison 08, outcome 05)
No study reported data on this outcome.

(9)Head and neck tissues

Primary outcomes
(a) Wound dehiscence (comparison 09, outcome 01)
Two trials reported this outcome (Marx 1999a; Marx 1999b), involving 368 subjects (65% of the total subjects in this review), with 184 randomised to both HBOT and control arms. Overall, 8 (6%) subjects in the HBOT arm suffered wound breakdown, versus 37 (28%) in the control group. Analysis for heterogeneity suggested a highproportion of variability between trials was not due to sampling variability (I^2=70%), and so this comparison was made using a random effects model. There was a significantly improved chance of wound breakdown with control (RR 4.2, 95% CI 1.1 to 16.8, P = 0.04). Stratification by tissue type involved confirmed the direction of effect was the same for both studies, but it remained significant only for soft tissue flaps and grafts (RR following hemimandibulectomy (Marx 1999a) 2.2, 95% CI 0.8 to 5.9, P = 0.12; RR following soft tissue flap or graft (Marx 1999b) 8.7, 95% CI 2.7 to 27.5, P = 0.0002). The number needed to treat with HBOT to avoid one wound dehiscience overall was 5 (95% CI 1 to 59), and for soft tissue repairs alone was 4 (95% CI 3 to 6). See Figure 3.

Figure 3. Forest plot of comparison: 11 Head and Neck, outcome: 11.1 Wound dehiscence.



(b) Surgical removal of the larynx (comparison 09, outcome 02)
No study reported data on this outcome.
(c) Major bleeding (comparison 09, outcome 03)
No study reported data on this outcome.
Secondary outcomes

(d) Speed of wound healing (comparison 09, outcome 04)
No study reported data on this outcome.
(e) Improvements in tissue quality (comparison 09, outcome 05)
No study reported data on this outcome.
(f) Reversal of tracheostomy (comparison 09, outcome 06)

No study reported data on this outcome.

(10) Urinary bladder (comparison10)

No study reported data on outcomes for this tissue.

(11) Chest wall (comparison 11)

No study reported data on outcomes for this tissue.

(12) Bowel (comparison 12)

No study reported data on outcomes for this tissue.

(13) Neurological tissue (comparison 13)

Primary outcomes

(a) Objective motor function (comparison 13, outcome 01)

No study reported data on this outcome.

(b) Visual acuity (comparison 13, outcome 02)

No study reported data on this outcome.

Secondary outcomes

(c) Warm sensory threshold at one week after therapy (comparison 13, outcome 03)

Only one trial reported this outcome (Pritchard 2001) involving 34 patients (6% of the total) with 17 randomised to both HBOT and control. The mean threshold temperature for reporting a warm sensation at one week after therapy (compared to pretreatment baseline) was reduced in the HBOT group, but not in the controls (-0.1 degree versus 1 degree). This difference was not statistically significant (WMD 1.1 degrees lower, 95% CI -1.9 to 4.1, P = 0.47).

(d) Warm sensory threshold at one year after therapy (comparison 13, outcome 04)

Only one trial reported this outcome (Pritchard 2001) involving 34 patients (6% of the total) with 17 randomised to both HBOT and control. The mean threshold for reporting a warm sensation was increased in both groups, but less so in controls (0.5 degrees versus 1.4). This difference was not statistically significant (WMD 0.9 degrees, 95% CI -2.3 to 4.0, P = 0.47).

(e) Functional ability scores and ADL (comparison 13, outcome 05)

No study reported data on this outcome.

(f) Net number of neuropsychological tests (maximum 25 tests) improved at three months (comparison 13, outcome 06)

Only one trial reported this outcome (Hulshof 2002) involving seven patients (1% of the total) with four randomised to HBOT and three to control. The mean net number of improved tests was greater in the HBOT group (3.3 versus 1.3), but not significantly so (WMD 2, 95% CI -1.6 to 5.0, P = 0.28).

(g) Net number of neuropsychological tests (maximum 25 tests) improved at six months (comparison 13, outcome 06)

Only one trial reported this outcome (Hulshof 2002) involving seven patients (1% of the total) with four randomised to HBOT and three to control. The mean net number of improved tests was greater in the HBOT group (3 versus 2), but not significantly so (WMD 1.1, 95% CI -3.6 to 5.6, P = 0.67).

(14) Adverse events

No study reported comparative data on these outcomes. Clarke 2008 gave overall figures for adverse events in all patients completing treatment. 19 (16%) patients complained of ear pain, 4 (3%) of transient myopia and 2 (1.7%) of confinement anxiety.

DISCUSSION

This review has identified eight trials investigating the use of HBOT for tissue suffering from late radiation damage, and we believe these represent all randomised human trials in this area, both published and unpublished, at the time of searching the databases. This review was updated in September 2008 and a new study including patients with established ORN (Annane 2004) was found, along with a full report for a study already identified in abstract (Clarke 2008). While both have infuenced the final results, neither has substantially altered our conclusions.

In general, these trials suggest a benefit from HBOT for non-neurological radiation tissue injury. The scant available evidence for neurological tissue is not encouraging. Any benefit from HBOT is not reflected in the results of Annane 2004. There are several reasons why this might be so. Firstly, this trial did not test the usual treatment regimen employed for the management of ORN and may not therefore be directly comparable with the other trials in this review. Case series data from the 1980s suggest that HBOT in isolation is not associated with a high resolution rate for established ORN and most centres now employ a combination of operative therapy, antibiotics and HBOT, as described by Marx (the Wilford Hall Protocol)(Marx 1983). One automatic definition of poor outcome for Annane 2004 was the requirement for operative therapy in cases presenting with less extensive disease, whether or not full recovery was eventually achieved. These cases would, however, be reported as successes in the other included trials. Secondly, 66 of the 134 patients (49%) presenting with ORN during the study period were ineligible for inclusion, making generalisation of the findings of this trial to more advanced cases of ORN (such as those presented in Marx 1999a and Marx 1999b) problematic. The first author has subsequently confirmed that "..one cannot use the findings of our study to decide the optimal treatment of severe forms of mandibular necrosis" (personal communication, April 2008). Thirdly, of the 50 patients in this trial that did not have a good outcome at one year, 34 were described as suffering previous treatment failure, which may have biased the result against superiority for either arm. Finally, this trial was stopped (according to pre-defined rules) with only 68 patients included and before a statistically significant result had been achieved. Any of these factors may have influenced the outcome of this trial. It is also possible that advances in care have taken place over time, such that HBOT no longer carries a therapeutic benefit.

The full report of Clarke 2008 generally confirms the results reported in abstract at an interim stage. The magnitude of effect for HBOT is reduced, but the direction remains in favour of HBOT. This trial did not present results for 31 of the 150 patients enrolled and sensitivity analysis for best and worst case outcomes in these missing patients has somewhat reduced our confidence in the effect of HBOT in radiation proctitis.

We found some evidence that HBOT improves the probability of healing in radiation proctitis and following hemimandibulectomy and reconstruction of the mandible; improves the probability of achieving mucosal coverage and the restoration of bony continuity with ORN; prevents the development of ORN following tooth extraction from a radiation field; and reduces the risk of wound dehiscence following grafts and flaps in the head and neck. Although there was some trend toward secondary favourable outcomes in neurological tissue, there was no evidence of benefit in important clinical outcomes with established radiation brachial plexus lesions or cerebral tissue injury. There was no data reported from any randomised trials involving the use of HBOT to treat other manifestations of radiation tissue damage.

Only eight trials with 566 participants were available for evaluation using our planned comparisons, and meta-analysis was not appropriate or possible for most of these. Many of the trials enrolled modest numbers of patients, particularly the trial investigating cerebral radiation injury, where only seven subjects were reported (Hulshof 2002). Other problems for this review were the poor methodological quality of some of these trials (particularly Marx 1999a; Marx 1999b), variability in entry criteria and the nature and timing of outcomes, and poor reporting of both outcomes and methodology. In particular, there is a possibility of bias in the combined tissue outcomes due to different anatomical locations and extent of tissue damage on entry to these trials, as well as from non-blinded management decisions in three of the trials (Marx 1985; Marx 1999a; Marx 1999b). Further, it is not clear when the subjects for Marx 1999a and Marx 1999b werer recruited - these trials may represent work from some years earlier.

These trials were published over a 23-year period up to 2008, and from a wide geographical area. We had planned to perform subgroup analyses with respect to anatomical location, dose of oxygen received (pressure, time and length of treatment course), nature of the comparative treatment modalities and the severity of injury. However, the paucity of eligible trials and poor reporting of some trials suggested that except for anatomical location, these analyses would not be informative. The oxygen dose used was reasonably standard over most trials. Patient inclusion criteria were not standard, and poorly reported in some trials. Specific comparator therapies were generally not employed.

Four trials reported on complete resolution of the clinical problem (Annane 2004; Clarke 2008; Marx 1999a; Pritchard 2001). Results varied widely and could not be pooled. Clarke 2008 and Marx 1999a reported significant improvement in the chance of healing radiation proctitis (RR 1.72, P = 0.04, NNT 5), and following hemi-mandibulectomy and reconstruction (RR 1.4, P = 0.001, NNT 4) respectively. Pritchard 2001, in contrast, reported no such resolution in any subject treated for established radiation brachial plexopathy. This difference in outcome could reflect the unresponsiveness of neurological tissue in general (an assertion supported by a similar lack of response for brain radiation injury in Hulshof 2002, or the relatively long-standing nature of the injuries enrolled in that trial (mean period from radiotherapy to HBOT was 11 years).

Pooling of data for clinical outcomes of interest could only be performed with respect to the the risk of wound dehiscience. This analysis suggested some benefit from HBOT administration (RR of dehiscience with control group was 4.2 [95% CI 1.1 to 16.8], NNT 5 [95% CI 3 to 8]). This result was subject to a high proportion of variability being due to differences between trials rather than to sampling variability, and the two trials were of relatively low quality. It should be interpreted with great caution. This possible treatment effect is, however, of great clinical importance and deserves further investigation.

The incidence of adverse effects was not systematically reported by the studies included in this review. There are a number of minor complications that may occur commonly. Visual disturbance, usually reduction in visual acuity secondary to conformational changes in the lens, is very commonly reported - perhaps as many as 50% of those having a course of 30 treatments (Khan 2003). While the great majority of patients recover spontaneously over a period of days to weeks, a small proportion of patients continue to require correction to restore sight to pre-treatment levels. Only four of 63 patients receiving HBOT in Clarke 2008 reported a reduction in visual acuity. All were temporary. The second most common adverse effect associated with HBOT is middle-ear barotrauma. Barotrauma can affect any air-filled cavity in the body (including the middle ear, lungs and respiratory sinuses) and occurs as a direct result of compression. Ear barotrauma is by far the most common as the middle ear air space is small, largely surrounded by bone and the sensitive tympanic membrane, and usually requires active effort by the patient in order to inflate the middle ear through the eustachian tube on each side. Barotrauma is thus not a consequence of HBOT directly, but rather of the physical conditions required to administer it. Most episodes of barotrauma are mild, easily treated or recover spontaneously and do not require the therapy to be abandoned.

While we have made every effort to locate further unpublished data, it remains possible that this review is subject to a positive publication bias, with generally favourable trials more likely to achieve reporting. With regard to long-term outcomes following HBOT and any effect on the QOL for these patients, we have located little relevant data.

AUTHORS' CONCLUSIONS

Implications for practice

There is some evidence that HBOT improves outcome in late radiation tissue injury affecting bone and soft tissues of the head and neck, for radiation proctitis and to prevent the development of osteoradionecrosis following tooth extraction in an irradiated field. There was no such evidence of any important clinical effect on neurological tissues, either peripheral or central. Thus, the application of HBOT to selected patients and tissues may be justified. Whilst the small number of studies, the modest numbers of patients and the methodological and reporting inadequacies of some of the primary studies included in this review demand a cautious interpretation, the pathology of radiation injury suggests that other tissues are also likely to respond (e.g. bladder). Further research is required to estabish the optimum patient selection and timing of any such therapy. An economic evaluation should also be undertaken.

Implications for research

There is a strong case for further large randomised trials of high methodological rigour in order to define the true extent of benefit from the administration of HBOT for patients with late radiation tissue injury. Specifically, more information is required on the subset of disease severity and tissue type affected that is most likely to benefit from this therapy, the time for which we can expect any benefits to persist, and the oxygen dose most appropriate. Any future trials would need to consider in particular:

Appropriate sample sizes with power to detect expected differences generated by this review

Careful definition and selection of target patients

Appropriate oxygen dose per treatment session (pressure and time)

Appropriate supportive therapy to which HBOT would be an adjunct

Use of an effective sham therapy

Effective and explicit blinding of outcome assessors

Appropriate outcome measures including all those listed in this review

Careful elucidation of any adverse effects

The cost-utility of the therapy

ACKNOWLEDGEMENTS

We thank Jill Porthouse, Clare Jess and Gail Quinn of the Cochrane Gynaecological Cancer Review Groupfor their assistance in the preparation of this review.

REFERENCES

References to studies included in this review

Annane 2004 ***{published data only (unpublished sought but not used)}***
Annane D, Depondt J, Aubert P, Villart M, Gehanno P, Gajdos P, Chevret S. Hyperbaric oxygen therapy for radionecrosis of the jaw: a randomized, placebo-controlled, double-blind trial from the ORN96 Study Group. *Journal of Clinical Oncology* 2004;**22**(24):4893–4900.

Clarke 2004 ***{unpublished data only}***
* Clarke D, Tenorio C, Dominguez L, Toklu A, Hussey J. Treatment of radiation necrosis with hyperbaric oxygen: A randomized double-blind placebo controlled trial. *Undersea and Hyperbaric Medicine* 2004;**31**(Suppl):000.

Clarke 2008 ***{published data only (unpublished sought but not used)}***
Clarke RE, Catalina Tenorio LM, Hussey JR, Toklu AS, Cone DL, Hinojosa JG, et al.Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomised and controlled double-blind crossover trial with long-term follow-up. *International Journal of Radiation Oncology, Biology, Physics* 2008;**72**:134–143.

Hulshof 2002 ***{published data only}***
* Hulshof M, Stark N, Van der Kleij A, Sminia P, Smeding H, Gonzales D. Hyperbaric oxygen therapy for cognitive disorders after irradiation of the brain. *Strahlentherapie und Onkologie* 2002;**178**(4): 192–8. [MEDLINE: 2002140155]

Marx 1985 ***{published data only}***
* Marx R, Johnson R, Kline S. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. *Journal of the American Dental Association* 1985;**111**(1): 49–54. [MEDLINE: 3897335]

Marx 1999a ***{published data only}***
* Marx R. Bony reconstruction of the jaw. In: Kindwall EP, Whelan HT editor(s). *Hyperbaric Medicine Practice*. 2nd Edition. Flagstaff, Az: Best Publishing, 1999:460–3. [MEDLINE: 0-941332-78-0]

Marx 1999b ***{published data only}***
* Marx RE. Soft tissue flaps. In: Kindwall EP, Whelan HT editor (s). *Hyperbaric Medicine Practice*. 2nd Edition. Flagstaff, Az: Best Publishing, 1999:464–8. [: 0–941332–78–0]

Pritchard 2001 ***{published data only}***
* Pritchard J, Anand P, Broome J, Davis C, Gothard L, Hall E, et al.Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. *Radiotherapy and Oncology* 2001;**58**(3):279–86. [MEDLINE: 2001084162]
Yarnold J. Double-blind randomised phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. *Radiotherapy and Oncology* 2005;**77**(3):327.

References to studies excluded from this review

Carl 2001 *{published data only}*

* Carl U, Feldmeier J, Schmitt G, Hartmann K. Hyperbaric oxygen therapy for late sequelae in women receiving radiation after breast-conserving surgery. *International Journal of Radiation Oncology Biology and Physics* 2001;**49**(4):1029–31. [MEDLINE: 11240244]

Coulthard 2002 *{published data only}*

Couthard P, Esposito M, Worthington H, Jokstad A. Interventions for replacing missing teeth: hyperbaric oxygen therapy for irradiated patients who require dental implants. *Cochrane Database of Systematic Reviews* 2002, Issue 3. Art No.: CD003603. DOI: 10.1002/14651858.CD003603. [DOI: CD003603. DOI: 10.1002/14651858.CD003603]

Denton 2002 *{published data only}*

Denton A, Forbes A, Andreyev J, Maher E. Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. *Cochrane Database of Systematic Reviews* 2002, Issue 1. Art No.: CD003455. DOI: 10.1002/14651858.CD003455. [DOI: CD003455. DOI: 10.1002/14651858.CD003455]

Gal 2003 *{published data only}*

* Gal T, Yueh B, Futran N. Influence of prior hyperbaric oxygen therapy in complications following microvascular reconstruction for advanced osteoradionecrosis. *Archives of Otolaryngology - Head & Neck Surgery* 2003;**129**(1):72–6. [MEDLINE: 2003027602]

Granstrom 1999 *{published data only}*

* Granstrom G, Tjellstrom A, Branemark P-I. Osseointegrated implants in irradiated bone: a case-controlled study using adjunctive hyperbaric oxygen therapy. *Journal of Oral and Maxillofacial Surgery* 1999;**57**:493–9. [: 0278–2391]

Maier 2000 *{published data only}*

* Maier A, Gaggl A, Klemen H, Santler G, Anegg U, Fell B, et al.Review of severe osteoradionecrosis treated by surgery alone or surgery with postoperative hyperbaric oxygenation. *British Journal of Oral and Maxillofacial Surgery* 2000;**38**(3):173–6. [MEDLINE: 10864721]

Niimi 1997 *{published data only}*

* Niimi A, Fujimoto T, Nosaka Y, Ueda M. A Japanese multicenter study of osseointegrated implants placed in irradiated tissues: a preliminary report. *International Journal of Oral and Maxillofacial Implants* 1997;**12**(2):259–64. [MEDLINE: 9109278]

Tobey 1979 *{published data only}*

* Tobey R, Kelly J. Osteoradionecrosis of the jaws. *Otolaryngology Clinics of North America* 1979;**12**(1):183–6. [MEDLINE: 375158]

References to studies awaiting assessment

Sidik 2007 *{published data only}*

Sidik S, Hardjodisastro D, Setiabudy R, Gondowiarjo S. Does hyperbaric oxygen administration decrease side effects and improve quality of life after pelvic irradiation?. *Acta Medica Indonesiana* 2007;**39**(4):169–173.

References to ongoing studies

Clarke 2004b *{published and unpublished data}*

Ongoing study Starting date of trial not provided. Contact author for more information.

Additional references

Altman 2001

Altman D, Chalmers I, Egger M, Davey Smith G. In: Egger M, Davey Smith G, Altman D editor(s). *Systematic reviews in health care. Meta-analysis in context*. 2. London: BMJ Books, 2001:333.

Bennett 2004

Bennett M, Connor D. The database of randomised controlled trials in hyperbaric medicine. http://www.hboevidence.com/ (accessed 06/08/04).

Davis 1988

Davis JC, Buckley CJ, Barr P. Compromised soft tissue wounds: correction of wound hypoxia. In: Davis JC, Hunt TK editor(s). *Problem Wounds. The Role of Oxygen*. New York: Elsevier, 1988: 143–52.

Feldmeier 1995

Feldmeier JJ, Heimbach RD, Davolt DA, Court WS, Stegmann BJ, Sheffield PJ. Hyperbaric oxygen as an adjunctive treatment for delayed radiation injury of the chest wall: a retrospective review of twenty-three cases. *Undersea and Hyperbaric Medicine* 1995;**22**(4): 383–93. [MEDLINE: 8574126]

Feldmeier 1998

Feldmeier JJ, Davolt DA, Court WS, Onoda JM, Alecu R. Histologic morphometry confirms a prophylactic effect for hyperbaric oxygen in the prevention of delayed radiation enteropathy. *Undersea and Hyperbaric Medicine* 1998;**25**(2):93–7. [MEDLINE: 9670434]

Feldmeier 2002

Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach. *Undersea and Hyperbaric Medicine* 2002;**29**(1):4–30. [MEDLINE: 12507182]

Feldmeier 2003

Feldmeier J, Carl U, Hartmann K, Sminia P. Hyperbaric oxygen: does it promote growth or recurrence of malignancy?. *Undersea and Hyperbaric Medicine* 2003;**30**(1):1–18. [MEDLINE: 12841604]

Higgins 2008

Higgins JPT, Green S editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. *The Cochrane Collaboration*. Available from www.cochrane-handbook.org, 2008.

Hills 1999

Hills BA. A role for oxygen-induced osmosis in hyperbaric oxygen therapy. *Medical Hypotheses* 1999;**52**:259–63.

Jemal 2002

Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. *CA: A Cancer Journal for Clinicians* 2002;**52**:23–47.

Khan 2003

Khan B, Evans AW, Easterbrook M. Refractive changes in patients undergoing hyperbaric oxygen therapy: a prospective study. *Undersea and Hyperbaric Medicine* 2003;**24 (Suppl)**:9.

Mainous 1975

Mainous EG, Hart GB. Osteoradionecrosis of the mandible. Treatment with hyperbaric oxygen. *Archives of Otolaryngology* 1975;**101** (3):173–7. [MEDLINE: 804303]

Mandell 1974

Mandell GL. Bactericidal activity of aerobic and anaerobic polymorphonuclear neutrophils. *Infection and Immunology* 1974;**9**:337–41.

Marx 1983

Marx RE. A new concept in the treatment ofosteoradionecrosis. *Journal of Oral and Maxillofacial Surgery* 1983;**41**:351–357.

Marx 1988

Marx RE, Johnson RP. Problem wounds in oral and maxillo-facial surgery: the role of hyperbaric oxygen. In: Davis JC, Hunt TK editor(s). *Problem Wounds: The Role of Oxygen*. New York: Elsevier, 1988:65–123.

Marx 1990

Marx RE, Ehler WJ, Tayapongsak P. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. *American Journal of Surgery* 1990;**160**:519–24.

Parmar 1998

Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. *Statistics in Medicine* 1998;**17**:2815–34. [: 9921604]

Pavy 1995

Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, et al.EORTC Late Effects Working Group. Late effects toxicity scoring: The SOMA scale. *Radiotherapy and Oncology* 1995;**35**:11-5.

Rubin 1968

Rubin P, Casarrett GW. *Clinical Radiation Pathology*. Vol. **1**, Philadelphia, PA: WB Saunders, 1968:58–61.

Rubin 1984

Rubin P. Late effects of chemotherapy and radiation therapy: a new hypothesis. *International Journal of Radiation Oncology, Biology and Physics* 1984;**10**:5–34.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *Journal of the American Medical Society* 1995;**273**(5):408–12.

Stone 2003

Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. *Lancet Oncology* 2003;**4**(9):529–36. [MEDLINE: 12965273]

Thompson 1999

Thompson IM, Middleton RG, Optenberg SA, Austenfeld MS, Smalley SR, Cooner WH, et al.Have complication rates decreased after treatment for localized prostate cancer?. *Journal of Urology* 1999; **162**(1):107–12. [MEDLINE: 10379751]

Trott 1984

Trott KR. Chronic damage after radiation therapy: challenge to radiation biology. *International Journal of Radiation Oncology, Biology and Physics* 1984;**10**:907–13.

Waddell 1999

Waddell BE, Rodriguez-Bigas MA, Lee RJ, Weber TK, Petrelli NJ. Prevention of chronic radiation enteritis. *Journal of the American College of Surgeons* 1999;**189**(6):611–24. [MEDLINE: 10589598]

WHO 2004

World Health Organization sites: Cancer. http: //www.who.int/cancer/en/ 2004.

* *Indicates the major publication for the study*

CHARACTERISTICS OF STUDIES

Characteristics of included studies *[ordered by study ID]*

Annane 2004

Methods	Multicentre RCT with central computerised allocation concealment and patient/outcome assessor blinding
Participants	Patients with overt osteoradionecrosis for at least two months despite antibiotics, local irrigation and surgery
Interventions	Control: 9% oxygen breathing at 2.4 ATA for 90 minutes 30 times over 3 weeks. If an operation was required, a further 10 treatments werre given post-operatively HBOT: 100% oxygen on the same schedule
Outcomes	Resolution of the problem, establishment of mucosal cover
Notes	This trial did not test the standard therapeutic approach because most participants were deemed to have failed if they required operative therapy

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Yes	

Clarke 2004

Methods	See Clarke 2008
Participants	68 patients
Interventions	See Clarke 2008
Outcomes	See Clarke 2008
Notes	Preliminary abstract report of one arm of 8 armed study

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Yes	

Clarke 2008

Methods	Multicentre RCT with central computerised allocation concealment and patient/outcome assessor blinding
Participants	150 patients with a three month history of radiation proctitis unresponsive to therapy
Interventions	Control: Air breathing at 1.1 ATA for 90 minutes 30 times over 6 weeks. Sham compression to trivial pressure and return. HBOT: 100% oxygen at 2.0 ATA for 30 or 40 sessions over six to eight weeks
Outcomes	Healing or significant improvement. LENT-SOMA Scores Quality of life assessment
Notes	Full report of the proctitis arm of this study

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Yes	Central computerised randomisation after enrollment

Hulshof 2002

Methods	Randomised trial using random number table with allocation concealement but no blinding. Randomised in matched pairs.
Participants	7 patients with cognitive deficits present at least 1.5 years after irradiation of the brain with at least 3000 cGy.
Interventions	Control: Nil specific HBOT: 100% oxygen at 3 ATA for 115 minutes for 30 sessions over six weeks (five days out of seven each week).
Outcomes	Neuropsychiatric testing
Notes	Very low power study with many outcomes

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Yes	A - Adequate

Marx 1985

Methods	Multicentre randomised trial. No details of methodology for randomisation , allocation concealment or blinding.
Participants	74 patients requiring tooth extraction in a field irradiated with at least 6000 cGy more than 6 months and less than 15 years previously. Also excluded with penicillin or HBOT contrandications, active tumour present, recent chemotherapy or concurrent disease (e.g. diabetes) that might affect wound healing.
Interventions	Control: teeth extracted in standard way with 1 million units penicilling pre-extraction and 500mg four times each day for 10 days post-extraction. HBOT: 20 pre-operative treatment sessions at 2.4 ATA for 90 minutes daily five or six days each week, followed by 10 further sessions post-operatively.
Outcomes	Development of clinical osteoradionecrosis with non-healing at 6 months
Notes	

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear

Marx 1999a

Methods	Described as randomised. No details concerning blinding or allocation concealment.
Participants	104 patients requiring hemimandibular jaw reconstruction in tissue beds exposed to at least 6400 cGy radiotherapy. No other specific exclusions.
Interventions	Control: Not stated HBOT: 20 pre-operative treatment sessions at 2.4 ATA for 90 minutes daily five days each week, followed by 10 further sessions post-operatively.
Outcomes	"Success" defined as achievement of continuity, restoration of alveolar bone height, restoration of osseous bulk, restoration of arch form, maintenance of bone form for 18 months and restoration of facial contours. Complication rate (infection or dehiscience).
Notes	Sketchy account within a textbook chapter written by the author.

Risk of bias

Item	Authors' judgement	Description
Allocation concealment?	Unclear	B - Unclear

Marx 1999b

Methods	Described as randomised. No details concerning blinding or allocation concealment.
Participants	160 patients requiring major soft tissue surgery or flaps into an irradiated area (>6,400 cGy). No other specific exclusions.
Interventions	Control: not stated HBOT: 20 pre-operative treatment sessions at 2.4 ATA for 90 minutes daily five days each week, followed by 10 further sessions post-operatively.
Outcomes	Wound infection, dehiscence, delayed healing
Notes	Sketchy account within a textbook chapter written by the author.

Risk of bias

Item	**Authors' judgement**	**Description**
Allocation concealment?	Unclear	B - Unclear

Pritchard 2001

Methods	Randomised, allocation concealed with blinding of outcome assessors and patients.
Participants	34 patients with established radiation-related brachial plexopathy, median duration 3 years. Subjects with active tumour or contraindications to HBOT excluded.
Interventions	Control: 100 minutes at 2.4 ATA breathing 41% oxygen to simulate 100% oxygen at 1ATA, daily 5 days per week to a total of 30 sessions. HBOT: 100% oxygen breathing on the same schedule.
Outcomes	Sensory thresholds, quality of life scores, McGill pain Score, lymphoedema resolution
Notes	Many other outcomes reported

Risk of bias

Item	**Authors' judgement**	**Description**
Allocation concealment?	Yes	A - Adequate

ATA: Atmospheres absolute
Brachial plexopathy: Poor functioning of the nerves going through the armpit to supply the arm and resulting in loss of sensation, muscle power and function in the arm.
cGy: Centi-Grey
HBOT: Hyperbaric oxygen therapy

Characteristics of excluded studies *[ordered by study ID]*

Carl 2001	Case series only, no randomised comparator
Coulthard 2002	Systematic review - no new data
Denton 2002	Systematic review - no new data
Gal 2003	Retrospective cohort study
Granstrom 1999	Case control study - not randomly allocated
Maier 2000	Retropective cohort study
Niimi 1997	Cohort study
Tobey 1979	RCT but no quantitative data given. Both arms received some HBOT (1.2 versus 2.0 ATA)

DATA AND ANALYSES

Comparison 1. Death

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death at one year	1	68	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.13, 5.61]

Comparison 2. Complete resolution of problem

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Complete resolution of clinical problem at three months	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 Proctitis	1	119	Risk Ratio (M-H, Fixed, 95% CI)	9.80 [0.55, 173.30]
1.2 Hemi-mandibular reconstruction	1	104	Risk Ratio (M-H, Fixed, 95% CI)	1.41 [1.14, 1.75]
1.3 Brachial plexus radiation neuropathy	1	34	Risk Ratio (M-H, Fixed, 95% CI)	Not estimable
1.4 Osteoradionecrosis	1	68	Risk Ratio (M-H, Fixed, 95% CI)	0.60 [0.25, 1.40]
2 Sensitivity analysis for missing data in proctitis (best case)	1	150	Risk Ratio (M-H, Fixed, 95% CI)	35.0 [2.14, 571.60]
3 Sensitivity analysis for missing data in proctitis (worst case)	1	150	Risk Ratio (M-H, Random, 95% CI)	0.26 [0.10, 0.67]
4 Sensitivity analysis for missing data in proctitis - (best case)	1	150	Risk Ratio (M-H, Fixed, 95% CI)	2.73 [1.66, 4.49]
5 Sensitivity analysis for proctitis - (worst case)	1	150	Risk Ratio (M-H, Fixed, 95% CI)	0.66 [0.47, 0.93]

Comparison 3. Complete resolution or significant improvement of problem

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Complete or significant improvement	1	119	Risk Ratio (M-H, Fixed, 95% CI)	1.72 [1.03, 2.86]
2 Sensitivity analysis for missing data in proctitis - (best case)	1	150	Risk Ratio (M-H, Fixed, 95% CI)	2.73 [1.66, 4.49]
3 Sensitivity analysis for missing data proctitis - (worst case)	1	150	Risk Ratio (M-H, Fixed, 95% CI)	0.66 [0.47, 0.93]

Comparison 4. Improvement in mean LENT-SOMA score

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mean LENT-SOMA score at three months	1	119	Mean Difference (IV, Fixed, 95% CI)	2.39 [0.88, 3.90]

Comparison 5. Resolution of pain

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Pain score change at end of treatment	1	34	Mean Difference (IV, Fixed, 95% CI)	Not estimable
2 Pain score change at one year	1	34	Mean Difference (IV, Fixed, 95% CI)	Not estimable

Comparison 6. Resolution of swelling

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Improvement of lymphoedema	1	34	Risk Ratio (M-H, Fixed, 95% CI)	5.0 [0.26, 97.00]

Comparison 7. Improvements in quality of life or function

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 SF-36 mean score at twelve months (general health)	1	34	Mean Difference (IV, Fixed, 95% CI)	-2.30 [-18.95, 14.35]
2 SF-36 mean score for physical function at 12 months	1	34	Mean Difference (IV, Fixed, 95% CI)	-4.0 [-19.40, 11.40]

Comparison 8. Osteoradionecrosis

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Complete mucosal cover	3	246	Risk Ratio (M-H, Random, 95% CI)	1.30 [1.09, 1.55]
2 Establishment of bony continuity	1	104	Risk Ratio (M-H, Fixed, 95% CI)	1.41 [1.14, 1.75]
3 Successful healing of tooth sockets after tooth extraction	1	74	Risk Ratio (M-H, Fixed, 95% CI)	1.35 [1.08, 1.68]

Comparison 9. Head and Neck

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Wound dehiscence	2	264	Risk Ratio (M-H, Random, 95% CI)	4.23 [1.06, 16.83]
1.1 Hemimandibular reconstruction (bone and soft tissue)	1	104	Risk Ratio (M-H, Random, 95% CI)	2.2 [0.82, 5.89]
1.2 Complex soft-tissue grafts/ flaps	1	160	Risk Ratio (M-H, Random, 95% CI)	8.67 [2.73, 27.49]

Comparison 13. Neurological tissue

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Warm sensory threshold one week after treatment (degrees Centigrade change from baseline)	1	34	Mean Difference (IV, Fixed, 95% CI)	1.12 [-1.90, 4.14]
2 Warm sensory threshold at one year	1	34	Mean Difference (IV, Fixed, 95% CI)	-0.87 [-3.97, 2.23]
3 Net number of significantly improved neuropsychological tests at three months (25 tests total)	1	7	Mean Difference (IV, Fixed, 95% CI)	2.00 [-1.60, 5.60]
4 Net number of significantly improved neuropsychiatric tests at six months	1	7	Mean Difference (IV, Fixed, 95% CI)	1.0 [-3.55, 5.55]

Analysis 1.1. Comparison 1 Death, Outcome 1 Death at one year.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 1 Death

Outcome: 1 Death at one year



Analysis 2.1. Comparison 2 Complete resolution of problem, Outcome 1 Complete resolution of clinical problem at three months.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 2 Complete resolution of problem

Outcome: 1 Complete resolution of clinical problem at three months



(*Continued . . .*)

(. . . *Continued*)

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Risk Ratio M-H,Fixed,95% CI
Pritchard 2001	0/17	0/17		0.0 [0.0, 0.0]
Subtotal (95% CI)	**17**	**17**		**0.0 [0.0, 0.0]**
Total events: 0 (HBOT), 0 (Control)				
Heterogeneity: not applicable				
Test for overall effect: Z = 0.0 (P < 0.00001)				
4 Osteoradionecrosis				
Annane 2004	6/31	12/37		0.60 [0.25, 1.40]
Subtotal (95% CI)	**31**	**37**		**0.60 [0.25, 1.40]**
Total events: 6 (HBOT), 12 (Control)				
Heterogeneity: not applicable				
Test for overall effect: Z = 1.18 (P = 0.24)				

Analysis 2.2. Comparison 2 Complete resolution of problem, Outcome 2 Sensitivity analysis for missing data in proctitis (best case).

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 2 Complete resolution of problem

Outcome: 2 Sensitivity analysis for missing data in proctitis (best case)

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Clarke 2004	17/75	0/75		100.0 %	35.00 [2.14, 571.60]
Total (95% CI)	**75**	**75**		**100.0 %**	**35.00 [2.14, 571.60]**
Total events: 17 (HBOT), 0 (Control)					
Heterogeneity: not applicable					
Test for overall effect: Z = 2.49 (P = 0.013)					



Analysis 2.3. Comparison 2 Complete resolution of problem, Outcome 3 Sensitivity analysis for missing data in proctitis (worst case).

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 2 Complete resolution of problem

Outcome: 3 Sensitivity analysis for missing data in proctitis (worst case)

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Random,95% CI	Weight	Risk Ratio M-H,Random,95% CI
Clarke 2004	5/75	19/75		100.0 %	0.26 [0.10, 0.67]
Total (95% CI)	**75**	**75**		**100.0 %**	**0.26 [0.10, 0.67]**
Total events: 5 (HBOT), 19 (Control)					
Heterogeneity: not applicable					
Test for overall effect: Z = 2.81 (P = 0.0050)					

Analysis 2.4. Comparison 2 Complete resolution of problem, Outcome 4 Sensitivity analysis for missing data in proctitis - (best case).

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 2 Complete resolution of problem

Outcome: 4 Sensitivity analysis for missing data in proctitis - (best case)

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Clarke 2008	41/75	15/75		100.0 %	2.73 [1.66, 4.49]
Total (95% CI)	**75**	**75**		**100.0 %**	**2.73 [1.66, 4.49]**
Total events: 41 (HBOT), 15 (Control)					
Heterogeneity: not applicable					
Test for overall effect: Z = 3.96 (P = 0.000074)					

Analysis 2.5. Comparison 2 Complete resolution of problem, Outcome 5 Sensitivity analysis for proctitis - (worst case).

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 2 Complete resolution of problem

Outcome: 5 Sensitivity analysis for proctitis - (worst case)

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Clarke 2008	29/75	44/75		100.0 %	0.66 [0.47, 0.93]
Total (95% CI)	**75**	**75**		**100.0 %**	**0.66 [0.47, 0.93]**
Total events: 29 (HBOT), 44 (Control)					
Heterogeneity: not applicable					
Test for overall effect: Z = 2.39 (P = 0.017)					

Analysis 3.1. Comparison 3 Complete resolution or significant improvement of problem, Outcome 1 Complete or significant improvement.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 3 Complete resolution or significant improvement of problem

Outcome: 1 Complete or significant improvement

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Clarke 2008	29/63	15/56		100.0 %	1.72 [1.03, 2.86]
Total (95% CI)	**63**	**56**		**100.0 %**	**1.72 [1.03, 2.86]**
Total events: 29 (HBOT), 15 (Control)					
Heterogeneity: not applicable					
Test for overall effect: Z = 2.09 (P = 0.037)					

Analysis 3.2. Comparison 3 Complete resolution or significant improvement of problem, Outcome 2 Sensitivity analysis for missing data in proctitis - (best case).

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 3 Complete resolution or significant improvement of problem

Outcome: 2 Sensitivity analysis for missing data in proctitis - (best case)

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Clarke 2008	41/75	15/75		100.0 %	2.73 [1.66, 4.49]
Total (95% CI)	**75**	**75**		**100.0 %**	**2.73 [1.66, 4.49]**
Total events: 41 (HBOT), 15 (Control)					
Heterogeneity: not applicable					
Test for overall effect: Z = 3.96 (P = 0.000074)					

Analysis 3.3. Comparison 3 Complete resolution or significant improvement of problem, Outcome 3 Sensitivity analysis for missing data proctitis - (worst case).

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 3 Complete resolution or significant improvement of problem

Outcome: 3 Sensitivity analysis for missing data proctitis - (worst case)

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Clarke 2008	29/75	44/75		100.0 %	0.66 [0.47, 0.93]
Total (95% CI)	**75**	**75**		**100.0 %**	**0.66 [0.47, 0.93]**
Total events: 29 (HBOT), 44 (Control)					
Heterogeneity: not applicable					
Test for overall effect: Z = 2.39 (P = 0.017)					



Analysis 4.1. Comparison 4 Improvement in mean LENT-SOMA score, Outcome 1 Mean LENT-SOMA score at three months.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 4 Improvement in mean LENT-SOMA score

Outcome: 1 Mean LENT-SOMA score at three months

Study or subgroup	HBOT N	Mean(SD)	Control N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI
Clarke 2004	63	5 (4.2)	56	2.61 (4.2)		100.0 %	2.39 [0.88, 3.90]
Total (95% CI)	**63**		**56**			**100.0 %**	**2.39 [0.88, 3.90]**

Heterogeneity: not applicable

Test for overall effect: Z = 3.10 (P = 0.0019)

Analysis 5.1. Comparison 5 Resolution of pain, Outcome 1 Pain score change at end of treatment.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 5 Resolution of pain

Outcome: 1 Pain score change at end of treatment

Study or subgroup	HBOT N	Mean(SD)	Control N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Mean Difference IV,Fixed,95% CI
Pritchard 2001	17	5.3 (0)	17	1.2 (0)		0.0 [0.0, 0.0]
Total (95% CI)	**17**		**17**			**0.0 [0.0, 0.0]**

Heterogeneity: not applicable

Test for overall effect: Z = 0.0 (P < 0.00001)



Analysis 5.2. Comparison 5 Resolution of pain, Outcome 2 Pain score change at one year.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 5 Resolution of pain

Outcome: 2 Pain score change at one year

Study or subgroup	HBOT N	Mean(SD)	Control N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Mean Difference IV,Fixed,95% CI
Pritchard 2001	17	-0.7 (0)	17	-5 (0)		0.0 [0.0, 0.0]
Total (95% CI)	**17**		**17**			**0.0 [0.0, 0.0]**

Heterogeneity: not applicable

Test for overall effect: Z = 0.0 (P < 0.00001)



Analysis 6.1. Comparison 6 Resolution of swelling, Outcome 1 Improvement of lymphoedema.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 6 Resolution of swelling

Outcome: 1 Improvement of lymphoedema

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Pritchard 2001	2/17	0/17		100.0 %	5.00 [0.26, 97.00]
Total (95% CI)	**17**	**17**		**100.0 %**	**5.00 [0.26, 97.00]**

Total events: 2 (HBOT), 0 (Control)

Heterogeneity: not applicable

Test for overall effect: Z = 1.06 (P = 0.29)

Analysis 7.1. Comparison 7 Improvements in quality of life or function, Outcome 1 SF-36 mean score at twelve months (general health).

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 7 Improvements in quality of life or function

Outcome: 1 SF-36 mean score at twelve months (general health)



Analysis 7.2. Comparison 7 Improvements in quality of life or function, Outcome 2 SF-36 mean score for physical function at 12 months.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 7 Improvements in quality of life or function

Outcome: 2 SF-36 mean score for physical function at 12 months



Analysis 8.1. Comparison 8 Osteoradionecrosis, Outcome 1 Complete mucosal cover.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 8 Osteoradionecrosis

Outcome: 1 Complete mucosal cover

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Random,95% CI	Weight	Risk Ratio M-H,Random,95% CI
Annane 2004	18/31	22/37		16.5 %	0.98 [0.65, 1.46]
Marx 1985	35/37	26/37		40.5 %	1.35 [1.08, 1.68]
Marx 1999a	48/52	34/52		43.1 %	1.41 [1.14, 1.75]
Total (95% CI)	**120**	**126**		**100.0 %**	**1.30 [1.09, 1.55]**

Total events: 101 (HBOT), 82 (Control)

Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 2.75$, df = 2 (P = 0.25); $I^2 = 27\%$

Test for overall effect: Z = 2.97 (P = 0.0030)

Analysis 8.2. Comparison 8 Osteoradionecrosis, Outcome 2 Establishment of bony continuity.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 8 Osteoradionecrosis

Outcome: 2 Establishment of bony continuity

Study or subgroup	HBOT n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% CI
Marx 1999a	48/52	34/52		100.0 %	1.41 [1.14, 1.75]
Total (95% CI)	**52**	**52**		**100.0 %**	**1.41 [1.14, 1.75]**

Total events: 48 (HBOT), 34 (Control)

Heterogeneity: not applicable

Test for overall effect: Z = 3.18 (P = 0.0015)

Analysis 8.3. Comparison 8 Osteoradionecrosis, Outcome 3 Successful healing of tooth sockets after tooth extraction.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 8 Osteoradionecrosis

Outcome: 3 Successful healing of tooth sockets after tooth extraction



Analysis 9.1. Comparison 9 Head and Neck, Outcome 1 Wound dehiscence.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 9 Head and Neck

Outcome: 1 Wound dehiscence



Analysis 13.1. Comparison 13 Neurological tissue, Outcome 1 Warm sensory threshold one week after treatment (degrees Centigrade change from baseline).

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 13 Neurological tissue

Outcome: 1 Warm sensory threshold one week after treatment (degrees Centigrade change from baseline)

Study or subgroup	Control N	Mean(SD)	HBOT N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI
Pritchard 2001	17	1 (3.92)	17	-0.12 (5.01)		100.0 %	1.12 [-1.90, 4.14]
Total (95% CI)	**17**		**17**			**100.0 %**	**1.12 [-1.90, 4.14]**

Heterogeneity: not applicable

Test for overall effect: Z = 0.73 (P = 0.47)

Analysis 13.2. Comparison 13 Neurological tissue, Outcome 2 Warm sensory threshold at one year.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 13 Neurological tissue

Outcome: 2 Warm sensory threshold at one year

Study or subgroup	Control N	Mean(SD)	HBOT N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI
Pritchard 2001	17	0.53 (3.43)	17	1.4 (5.54)		100.0 %	-0.87 [-3.97, 2.23]
Total (95% CI)	**17**		**17**			**100.0 %**	**-0.87 [-3.97, 2.23]**

Heterogeneity: not applicable

Test for overall effect: Z = 0.55 (P = 0.58)



Analysis 13.3. Comparison 13 Neurological tissue, Outcome 3 Net number of significantly improved neuropsychological tests at three months (25 tests total).

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 13 Neurological tissue

Outcome: 3 Net number of significantly improved neuropsychological tests at three months (25 tests total)

Study or subgroup	HBOT N	Mean(SD)	Control N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI
Hulshof 2002	4	3.3 (3.4)	3	1.3 (1.2)		100.0 %	2.00 [-1.60, 5.60]
Total (95% CI)	**4**		**3**			**100.0 %**	**2.00 [-1.60, 5.60]**

Heterogeneity: not applicable

Test for overall effect: Z = 1.09 (P = 0.28)

Analysis 13.4. Comparison 13 Neurological tissue, Outcome 4 Net number of significantly improved neuropsychiatric tests at six months.

Review: Hyperbaric oxygen therapy for late radiation tissue injury

Comparison: 13 Neurological tissue

Outcome: 4 Net number of significantly improved neuropsychiatric tests at six months

Study or subgroup	HBOT N	Mean(SD)	Control N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI
Hulshof 2002	4	3 (4.5)	3	2 (1)		100.0 %	1.00 [-3.55, 5.55]
Total (95% CI)	**4**		**3**			**100.0 %**	**1.00 [-3.55, 5.55]**

Heterogeneity: not applicable

Test for overall effect: Z = 0.43 (P = 0.67)



APPENDICES

Appendix 1. MEDLINE search strategy (via OVID)

1. exp radiation injuries/
2. radiotherapy/ae
3. (radiation or radiother$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
4. (damage$ or injur$ of wound$ or destruction or oedema or edema or fracture$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
5. 4 and 3
6. 1 or 2 or 5
7. exp hyperbaric oxygenation/
8. (high adj3 pressure).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
9. (high adj3 tension).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
10. (hyperbaric and oxygen$).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
11. (HBO or HBOT).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
12. (multiplace chamber$ or multiplace hyperbaric chamber$).mp.
13. (monoplace chamber$ or monoplace hyperbaric chamber$).mp.
14. 8 or 11 or 7 or 13 or 10 or 9 or 12
15. 6 and 14
16. randomized controlled trial.pt.
17. controlled clinical trial.pt.
18. randomized.ti. or randomized.ab.
19. randomly.ti. or randomly.ab.
20. trial.ti. or trial.ab.
21. groups.ti. or groups.ab.
22. 21 or 18 or 19 or 16 or 17 or 20
23. Animals/
24. Humans/
25. 23 not (23 and 24)
26. 22 not 25
27. 26 and 15

Appendix 2. EMBASE search strategy

1. exp Radiation Injury/
2. radiotherapy/ae
3. (radiation or radiother$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
4. (damage$ or injur$ of wound$ or destruction or oedema or edema or fracture$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
5. 4 and 3
6. 1 or 2 or 5
7. exp hyperbaric oxygenation/
8. (high adj3 pressure).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
9. (high adj3 tension).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
10. (hyperbaric and oxygen$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
11. (hbo or hbot).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
12. (multiplace chamber$ or multiplace hyperbaric chamber$).mp.

13. (monoplace chamber$ or monoplace hyperbaric chamber$).mp.
14. 8 or 11 or 7 or 13 or 10 or 9 or 12
15. 6 and 14
16. Randomized Controlled Trial/
17. Controlled Clinical Trial/
18. randomized.ti. or randomized.ab.
19. randomly.ti. or randomly.ab.
20. trial.ti. or trial.ab.
21. groups.ti. or groups.ab.
22. 21 or 18 or 19 or 16 or 17 or 20
23. Animal/
24. Human/
25. 23 not (23 and 24)
26. 22 not 25
27. 26 and 15

Appendix 3. CINAHL Search Strategy

1. exp radiation injuries/
2. RADIOTHERAPY/ae
3. (radiation or radiother*).mp.
4. (damage* or injur* of wound* or destruction or oedema or edema or fracture*).mp.
5. 4 and 3
6. 1 or 2 or 5
7. exp hyperbaric oxygenation/
8. (high adj3 pressure).mp.
9. (high adj3 tension).mp.
10. (hyperbaric and oxygen$).mp.
11. (HBO or HBOT).mp.
12. (multiplace chamber$ or multiplace hyperbaric chamber$).mp.
13. (monoplace chamber$ or monoplace hyperbaric chamber$).mp.
14. 8 or 11 or 7 or 13 or 10 or 9 or 12
15. 6 and 14
16. exp Clinical Trials/
17. (randomized or controlled).mp.
18. 16 and 17
19. randomized controlled trial.mp.
20. controlled clinical trial.mp.
21. randomized.ti,ab.
22. randomly.ti,ab.
23. trial.ti,ab.
24. groups.ti,ab.
25. 22 or 21 or 18 or 24 or 23 or 19 or 20
26. Animals/
27. (man or woman or human being).mp.
28. 26 not (26 and 27)
29. 25 not 28
30. 29 and 15

Appendix 4. CENTRAL Search Strategy

1. (hyperbaric in All Text and oxygen* in All Text)
2. MeSH descriptor Hyperbaric Oxygenation explode all trees
3. (#1 or #2)
4. MeSH descriptor Radiation Injuries explode all trees
5. radiation in All Text
6. radiother* in All Text
7. (#4 or #5 or #6)
8. (#3 and #7)

Appendix 5. DORCTIHM Search Strategy

1. Radiotherapy OR radiation tissue injury OR late radiation effect

WHAT'S NEW

Last assessed as up-to-date: 22 August 2008.

23 August 2008	New search has been performed	Two new trials identifed and added to review when searches were re-run in August 2008.

HISTORY

Protocol first published: Issue 2, 2004

Review first published: Issue 3, 2005

26 April 2008	Amended	Converted to new review format.
23 May 2005	New citation required and conclusions have changed	Substantive amendment

CONTRIBUTIONS OF AUTHORS

Michael Bennett: Principal author, conception, search strategy and execution, data extraction and critical appraisal, hyperbaric medicine content expert, statistical analysis. John Feldmeier: Co-author, data extraction and critical appraisal, radiation oncology and hyperbaric medicine content expert. Neil Hampson: Co-author, editorial advice, data extraction and critical appraisal, hyperbaric medicine content expert. Chris Milross: Co-author background, radiation oncology content expert. Robert Smee: Editorial advice, radiation oncology content expert.

DECLARATIONS OF INTEREST

None known. Bennett and Hampson are hyperbaric physicians who regularly treat patients with late radiation tissue injury, while Feldmeier has previous hyperbaric experience. Milross, Feldmeier and Smee are radiation oncologists who refer patients with late radiation tissue injury for HBOT.

INDEX TERMS

Medical Subject Headings (MeSH)

*Hyperbaric Oxygenation; Neoplasms [radiotherapy]; Osteoradionecrosis [prevention & control]; Radiation Injuries [prevention & control; *therapy]; Randomized Controlled Trials as Topic

MeSH check words

Humans